Modeling in vivo relative biological effectiveness in particle therapy for clinically relevant endpoints

Authors

  • Armin Lühr OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden – Rossendorf, Dresden, Germany; ;Helmholtz-Zentrum Dresden ? Rossendorf, Institute of Radiooncology – OncoRay, Dresden, Germany; ;German Cancer Consortium (DKTK), Partner Site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany
  • Cläre von Neubeck OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden – Rossendorf, Dresden, Germany; ;German Cancer Consortium (DKTK), Partner Site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany
  • Stephan Helmbrecht OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden – Rossendorf, Dresden, Germany
  • Michael Baumann OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden – Rossendorf, Dresden, Germany; ;Helmholtz-Zentrum Dresden ? Rossendorf, Institute of Radiooncology – OncoRay, Dresden, Germany; ;German Cancer Research Center (DKFZ), Heidelberg, Germany; ;National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany
  • Wolfgang Enghardt OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden – Rossendorf, Dresden, Germany; ;Helmholtz-Zentrum Dresden ? Rossendorf, Institute of Radiooncology – OncoRay, Dresden, Germany; ;German Cancer Consortium (DKTK), Partner Site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany; ;National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany; ;Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
  • Mechthild Krause OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden – Rossendorf, Dresden, Germany; ;Helmholtz-Zentrum Dresden ? Rossendorf, Institute of Radiooncology – OncoRay, Dresden, Germany; ;German Cancer Consortium (DKTK), Partner Site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany; ;National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany; ;Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

DOI:

https://doi.org/10.1080/0284186X.2017.1356468

Abstract

Background: The relative biological effectiveness (RBE) of particle therapy compared to photon radiotherapy is known to be variable but the exact dependencies are still subject to debate. In vitro data suggested that RBE is to a large extend independent of ion type if parametrized by the beam quality Q. This study analyzed the RBE dependence of pre-clinical data on late toxicity with an emphasis on the beam quality.

Material and methods: Published pre-clinical RBE dose-response data of the spinal cord following one and two fractions of photon and carbon ion irradiation were compiled. The beam quality for each treatment condition was obtained from Monte Carlo simulations. The αp and βp parameters of the linear-quadratic (LQ) model for particle irradiation were determined from the pre-clinical data and was provided as a function of Q. An introduced model proposed αp to increase linearly with Q and βp to remain constant. RBE values predicted by the model were compared to the published data.

Results: The αp parameter was highly correlated with Q (R2 = 0.96) with a linear slope of 0.019 Gy−1. No significant variation of βp with Q was found. RBE and Q were also highly correlated (R2 = 0.98) for one and two fractions. The (extrapolated) RBE at Q = 0 (theoretical photon limit) for one and two fractions was 1.22 and significantly larger than 1 (p = .004). The model reproduced the dependence of RBE on fractionation well.

Conclusions: Fraction dose and beam quality Q were sufficient to describe the RBE variability for a late toxicity model within a carbon ion treatment field. Assuming the independence of the identified RBE parameters on the ion type might suggest the translation of variable (pre-) clinical RBE data from carbon ion to proton therapy.

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2017-11-02

How to Cite

Lühr, A., von Neubeck, C., Helmbrecht, S., Baumann, M., Enghardt, W., & Krause, M. (2017). Modeling in vivo relative biological effectiveness in particle therapy for clinically relevant endpoints. Acta Oncologica, 56(11), 1392–1398. https://doi.org/10.1080/0284186X.2017.1356468